• Caliper Life Sciences (Hopkinton, Massachusetts) has introduced Bioware Ultra cell lines, a range of ultra-bright, light-producing tumor cell lines created for in vivo imaging applications. Bioware Ultra cell lines are 10 to 100 times brighter than cell lines created using traditional methods, which allows researchers, for the first time ever, to detect a single cancer cell in an animal via non-invasive in vivo imaging. In vivo imaging provides researchers with the ability to recognize tumor growth and behaviors at the cellular level within living animals. By tagging a tumor with the gene for luciferase, the same gene that allows a firefly to glow, the tumor can produce light that can be monitored using Caliper's IVIS imaging systems. Caliper Life Sciences specializes in microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions.

• SheerVision (Rolling Hills Estates, California) reported the launch of its new FireFly Infinity Ultra headlight system. The main enhancement of this headlight system is the new lithium-polymer battery and charging system. The FireFly combines its 54,000+ Lux beam with a lightweight lithium-polymer battery. The FireFly weighs less than one ounce and has a light life of 50,000 hours. SheerVision makes surgical loupes and light systems.

• SynCardia Systems (Tucson, Arizona) reported the introduction of the prototype of its new 4-pound Companion II Driver, the next step in its Companion Driver System series. The Companion Drive System is designed to be docked into the Companion Hospital Cart for use in the operating room and intensive care unit. Once the CardioWest artificial heart patient is stable, the Drive Unit is designed to be re-docked into the Companion Discharge Caddy for mobility around the hospital and recovery at home. SynCardia Systems makes the CardioWest temporary total artificial heart.

• Synthetic Blood International (Costa Mesa, California) said it has filed a clinical protocol with the FDA for its planned Phase II-b clinical trial of Oxycyte in traumatic brain injury patients. Oxycyte is the company's perfluorocarbon therapeutic oxygen carrier and blood substitute. Synthetic Blood International makes pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring.

• VisEn Medical (Woburn, Massachusetts) reported the commercial launch of its FMT 2500 small-animal imaging system. The FMT 2500 is based on VisEn's fluorescence molecular tomography (FMT) technology platform, and combined with VisEn's portfolio of fluorescence in vivo imaging agents, assists researchers to generate quantitative data on disease biologies and therapeutic response profiles in animal research models. The FMT technology platform enables quantitative tomographic in vivo data by using three key steps: data generation, data normalization, and fluorescence tomographic reconstruction. Using a FMT 2500 animal imaging cassette that is compatible with multiple imaging modalities, researchers can also co-register FMT data with imaging readouts from other modalities, including CT, MR and PET. VisEn focuses on fluorescence in vivo imaging.